Table 1. Patients’ clinicopathological characteristics and associations with the AJCC N factor, LNR and LODDS.
| Characteristics | All case | AJCC N factor | LNR | LODDS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| pN− (N0) | pN+ (N1–3) | P | L-LNR | H-LNR | P | L-LODDS | H-LODDS | P | ||||
| Cases | 738 | 207 | 531 | 452 | 286 | 442 | 296 | |||||
| Age | ||||||||||||
| Median (IQR) | 36 (32–39) | 36 (32–39) | 36 (32–38) | 0.553 | 36 (32–39) | 36 (32–38) | 0.213 | 36 (32–39) | 36 (32–38.8) | 0.203 | ||
| Race | ||||||||||||
| White | 480 (65.1) | 129 (62.3) | 351 (66.1) | 0.368 | 288 (63.7) | 192 (67.1) | 0.573 | 284 (64.3) | 196 (66.2) | 0.684 | ||
| Black | 94 (12.7) | 32 (15.5) | 62 (11.7) | 58 (12.8) | 36 (12.6) | 55 (12.4) | 39 (13.2) | |||||
| Others†/NOS | 164 (22.2) | 46 (22.2) | 118 (22.2) | 106 (23.5) | 58 (20.3) | 103 (23.3) | 61 (20.6) | |||||
| Gender | ||||||||||||
| Male | 352 (47.7) | 96 (46.4) | 256 (48.2) | 0.654 | 210 (46.5) | 142 (49.7) | 0.398 | 205 (46.4) | 147 (49.7) | 0.382 | ||
| Female | 386 (52.3) | 111 (53.6) | 275 (51.8) | 242 (53.5) | 144 (50.3) | 237 (53.6) | 149 (50.3) | |||||
| Insurance | ||||||||||||
| Yes | 481 (65.2) | 151 (72.9) | 330 (62.1) | 0.006* | 320 (70.8) | 161 (56.3) | <0.001* | 316 (71.5) | 165 (55.7) | <0.001* | ||
| No/unknown | 257 (34.8) | 56 (27.1) | 201 (37.9) | 132 (29.2) | 125 (43.7) | 126 (28.5) | 131 (44.3) | |||||
| Marital status | ||||||||||||
| Married | 435 (59.0) | 107 (51.7) | 328 (61.8) | 0.004* | 262 (58.0) | 173 (60.5) | 0.825 | 258 (58.4) | 177 (59.8) | 0.969 | ||
| Single | 246 (33.3) | 75 (36.2) | 171 (32.2) | 155 (34.3) | 91 (31.9) | 150 (33.9) | 96 (32.4) | |||||
| Separated/divorced/widowed | 36 (4.9) | 13 (6.3) | 23 (4.3) | 21 (4.6) | 15 (5.2) | 21 (4.8) | 15 (5.1) | |||||
| NOS | 21 (2.8) | 12 (5.8) | 9 (1.7) | 14 (3.1) | 7 (2.4) | 13 (2.9) | 8 (2.7) | |||||
| Tumor subsites | ||||||||||||
| Cardia | 110 (14.9) | 26 (12.6) | 84 (15.8) | 0.183 | 69 (15.3) | 41 (14.3) | <0.001* | 68 (15.4) | 42 (14.2) | 0.002* | ||
| Middle | 223 (30.2) | 71 (34.3) | 152 (28.6) | 151 (33.4) | 72 (25.2) | 146 (33.0) | 77 (26.0) | |||||
| Distal | 268 (36.3) | 71 (34.3) | 167 (31.5) | 153 (33.8) | 85 (29.7) | 149 (33.7) | 89 (30.1) | |||||
| Overlapping/NOS | 167 (22.6) | 39 (18.8) | 128 (24.1) | 79 (17.5) | 88 (30.8) | 79 (17.9) | 88 (29.7) | |||||
| Differentiation | ||||||||||||
| Well differentiated | 9 (1.2) | 6 (2.9) | 3 (0.6) | <0.001* | 9 (2.0) | 0 | 0.047* | 9 (2.0) | 0 | 0.022* | ||
| Moderately differentiated | 71 (9.6) | 26 (12.6) | 45 (8.4) | 50 (11.1) | 21 (7.3) | 50 (11.3) | 21 (7.1) | |||||
| Poorly differentiated | 595 (80.7) | 149 (72.0) | 446 (84.0) | 355 (78.5) | 240 (83.9) | 346 (78.3) | 249 (84.1) | |||||
| Undifferentiated | 26 (3.5) | 5 (2.4) | 21 (4.0) | 14 (3.1) | 12 (4.2) | 13 (3.0) | 13 (4.4) | |||||
| Unknown | 37 (5.0) | 21 (10.1) | 16 (3.0) | 24 (5.3) | 13 (4.6) | 24 (5.4) | 13 (4.4) | |||||
| Histological type | ||||||||||||
| Diffuse | 437 (59.2) | 131 (63.3) | 306 (57.6) | 0.217 | 267 (59.1) | 170 (59.4) | 0.611 | 260 (58.8) | 177 (59.8) | 0.673 | ||
| Intestinal | 264 (35.8) | 64 (30.9) | 200 (37.7) | 165 (36.5) | 99 (34.6) | 162 (36.7) | 102 (34.5) | |||||
| Other | 37 (5.0) | 12 (5.8) | 25 (4.7) | 20 (4.4) | 17 (6.0) | 20 (4.5) | 17 (5.7) | |||||
| Tumor size | ||||||||||||
| <1 cm | 45 (6.1) | 41 (19.8) | 4 (0.8) | <0.001* | 44 (9.7) | 1 (0.3) | <0.001* | 44 (10.0) | 1 (0.3) | <0.001* | ||
| 1–2 cm | 51 (6.9) | 33 (15.9) | 18 (3.4) | 45 (10.0) | 6 (2.1) | 45 (10.2) | 6 (2.0) | |||||
| 2–3 cm | 69 (9.4) | 29 (14.0) | 40 (7.5) | 55 (12.2) | 14 (4.9) | 55 (12.4) | 14 (4.7) | |||||
| 3–4 cm | 88 (11.9) | 16 (7.7) | 72 (13.6) | 57 (12.6) | 31 (10.9) | 55 (12.4) | 33 (11.2) | |||||
| 4–5 cm | 70 (9.5) | 13 (6.3) | 57 (10.7) | 41 (9.1) | 29 (10.1) | 40 (9.0) | 30 (10.2) | |||||
| ≥5 cm | 319 (43.2) | 38 (18.4) | 281 (52.9) | 145 (32.1) | 174 (60.8) | 139 (31.5) | 180 (60.8) | |||||
| NOS | 96 (13.0) | 37 (17.9) | 59 (11.1) | 65 (14.3) | 31 (10.9) | 64 (14.5) | 32 (10.8) | |||||
| The median number of total LNs examined (IQR) | 17 (11–27) | 14 (8–23) | 18 (12–27) | <0.001* | 18 (11–29) | 16 (10–23) | 0.001* | 18 (11–29) | 16 (10–23) | 0.001* | ||
| The number of total LNs examined | ||||||||||||
| ≤15 | 321 (43.5) | 117 (56.5) | 204 (38.4) | <0.001* | 186 (41.2) | 135 (47.2) | 0.106 | 181 (41.0) | 140 (47.3) | 0.088 | ||
| >15 | 417 (56.5) | 90 (43.5) | 327 (61.6) | 266 (58.8) | 151 (52.8) | 261 (59.0) | 156 (52.7) | |||||
| T stage | ||||||||||||
| T1 | 118 (16.0) | 101 (48.8) | 17 (3.2) | <0.001* | 117 (25.8) | 1 (0.3) | <0.001* | 117 (26.5) | 1 (0.3) | <0.001* | ||
| T2 | 185 (25.1) | 46 (22.2) | 139 (26.2) | 121 (26.8) | 64 (22.4) | 121 (27.4) | 64 (21.6) | |||||
| T3 | 239 (32.3) | 33 (16.0) | 206 (38.7) | 121 (26.8) | 118 (41.3) | 116 (26.2) | 123 (41.6) | |||||
| T4 | 193 (26.2) | 27 (13.0) | 166 (31.3) | 92 (20.4) | 101 (35.3) | 87 (19.7) | 106 (35.7) | |||||
| TX | 3 (0.4) | 0 | 3 (0.6) | 1 (0.2) | 2 (0.7) | 1 (0.2) | 2 (6.8) | |||||
| M stage | ||||||||||||
| M0 | 584 (79.1) | 191 (92.3) | 393 (74.0) | <0.001* | 398 (88.1) | 186 (65.0) | <0.001* | 391 (88.5) | 193 (65.2) | <0.001* | ||
| M1 | 154 (20.9) | 16 (7.7) | 138 (26.0) | 54 (11.9) | 100 (35.0) | 51 (11.5) | 103 (34.8) | |||||
| Chemotherapy | ||||||||||||
| Yes | 543 (73.6) | 94 (45.4) | 449 (84.6) | <0.001* | 314 (69.5) | 229 (80.1) | 0.001* | 306 (69.2) | 237 (80.1) | 0.001* | ||
| No/unknown | 195 (26.4) | 113 (54.6) | 82 (15.4) | 138 (30.5) | 57 (19.9) | 136 (30.8) | 59 (19.9) | |||||
| Radiotherapy | ||||||||||||
| Yes | 293 (39.7) | 45 (21.7) | 248 (46.7) | <0.001* | 173 (38.3) | 120 (42.0) | 0.319 | 169 (38.2) | 124 (41.9) | 0.320 | ||
| No/unknown | 445 (60.3) | 162 (78.3) | 283 (53.3) | 279 (61.7) | 166 (58.0) | 273 (61.8) | 172 (58.1) | |||||
LNR, lymph node ratio; LODDS, the log odds of positive lymph nodes; NOS, not otherwise specified; LN, lymph node. *, indicate significant P values. †, Others, American Indian/AK Native, Asian/Pacific Islander.